Form 4: Immunovant CEO Settles Stock Options, Sells Shares

Immunovant CEO Eric Venker settled vested appreciation rights and sold shares to cover tax obligations, as detailed in a Form 4 filing.

Summary

• Eric Venker, CEO of Immunovant, Inc., engaged in transactions involving the settlement of Capped Value Appreciation Rights (CVARs) and the subsequent sale of shares.
• On July 1, 2026, 92,188 vested CVARs were settled into common stock. These CVARs were originally granted on July 28, 2025, with a hurdle price of $14.46 and a cap of $16.76 per share.
• The settlement resulted in the acquisition of 92,188 shares of common stock.
• Following the settlement, Venker sold 3,092 shares of common stock on July 2, 2026, at a price of $38.48 per share.
• This sale was to cover tax withholding obligations arising from the vesting and settlement of the CVARs, as per the company's 'sell to cover' policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves executive stock transactions, the 'sell to cover' nature for tax withholding suggests it's a planned event rather than a market signal.

Positives

• Vesting and settlement of 92,188 CVARs indicate progress towards performance and service requirements tied to the equity awards.
• The CEO's continued service and the satisfaction of performance requirements for the CVARs suggest positive operational or clinical development milestones may have been met.
• The 'sell to cover' transaction for tax withholding is a standard procedure and does not necessarily indicate a discretionary sale of stock by the CEO.

Negatives

• The filing details a sale of shares, which could be perceived negatively by the market, although it is for tax withholding purposes.
• The capped value of the appreciation rights at $16.76 per share implies a limit on the potential upside for these specific awards, even if the stock price exceeds this level.

Risks

• The 'Knock-in Requirement' for CVARs, which mandates the stock price to be at or above $16.76 per share on vesting dates, presents a risk if the stock price does not meet this threshold.
• The vesting of the remaining 75% of CVARs is subject to the Reporting Person's continuous service, posing a risk of forfeiture if service is terminated.

Future Outlook

The remaining 75% of CVARs vest in twelve equal quarterly installments after April 1, 2026, subject to continuous service. The settlement of these rights into shares is contingent on the stock price meeting the 'Knock-in Requirement' of $16.76 per share at each applicable vesting date.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors, detailing changes in beneficial ownership. The settlement of appreciation rights and subsequent 'sell to cover' transactions are common practices for managing tax liabilities associated with equity compensation in the biotechnology and pharmaceutical sectors, where Immunovant operates.

Stakeholder Impact

• Shareholders: The sale of shares is for tax withholding and not a discretionary sale, thus likely to have minimal negative impact on share price perception. The settlement of rights indicates progress on executive compensation plans.
• Employees: The successful satisfaction of performance requirements for executive compensation may indirectly reflect positive company performance, potentially benefiting employees.
• Management: The CEO's ability to manage tax liabilities through 'sell to cover' demonstrates effective financial planning related to compensation.

Next Steps

• Continued vesting of the remaining 75% of CVARs in quarterly installments, subject to service and stock price requirements.
• Potential future 'sell to cover' transactions for tax withholding as additional equity awards vest and settle.

Key Dates

Keywords

Form 4, SEC Filing, Immunovant, IMVT, Eric Venker, CEO, Stock Options, Appreciation Rights, CVARs, Share Settlement, Tax Withholding, Insider Trading, Beneficial Ownership